Dr. Patrick Doucette, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 910 O St, Firebaugh, CA 93622 Phone: 559-659-1491 Fax: 559-659-6130 |
News Archive
Anadys Pharmaceuticals, Inc. today announced preliminary results from an ongoing Phase II study demonstrating that 73% of hepatitis C patients treated with 200 mg ANA598 twice daily in combination with pegylated interferon and ribavirin (SOC) achieved undetectable levels of virus (<15 IU/mL) at week 12, known as complete Early Virological Response or cEVR.
The statistics and dangers are real. Yet according to the National Safety Council, on average, there are still more than three dozen children dying in parked cars every year. In 2018, that number climbed to 52. There were three cases that made the news just in the past two weeks.
Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.
Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist.
There's no need to reinvent the genetic wheel. That's one lesson of a new study that looks to the saliva of humans, gorillas, orangutans, macaques and African green monkeys for insights into evolution.
› Verified 7 days ago